The contractor shall provide preclinical development support for candidate products and drug development activities. The scope of work encompasses activities that range from initial product…
Active Awarded Last action
- Contract number
- 75N93021D00011
- Awardee
-
University Of Texas Medical Branch At Galveston UEI MSPWVMXXMN76 Part of University Of Texas System
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 4 $1,139,096 obligated
Award facts
- Opportunity
-
- Preclinical Services for HIV Therapeutics Pre-Solicitation · 75N93019R00021 · Posted Oct 4, 2019
- Preclinical Services for HIV Therapeutics Solicitation · Posted Dec 5, 2019
- Combined order value
- $1,139,096 Current and potential, with all options
- Last date to order 86% complete
- IDV ceiling 1% used
- $107,274,471.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded a multiple-award indefinite-delivery contract to University Of Texas Medical Branch At Galveston on October 15, 2020, with a ceiling value of $107,274,471 and an ultimate completion date of October 14, 2027. The contract provides preclinical development support for candidate products and drug development activities spanning from initial product discovery through activities required to support clinical trials and product licensure.
Performance takes place in Galveston, Texas. The originating solicitation (posted October 4, 2019) solicited proposals across seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV, hepatitis B, hepatitis C, and mycobacterium, formulation development and clinical dosage manufacturing, preclinical pharmacology and toxicology, and a reagent program for HIV and other infectious diseases. Task Area B (synthesis of therapeutic agents) carried a small business set-aside under NAICS 541715 with a 1,000-employee size standard; the overall program is multiple-award without set-aside restriction. The solicitation anticipated 6–21 task orders annually, valued at approximately $500,000 to $5,000,000 each, with an anticipated seven-year performance period.
Recent delivery orders issued under this IDIQ include testing of a novel inhaled clofazimine dry powder formulation in a mouse model of Mycobacterium tuberculosis ($788,445, August 2023, due September 2025); testing of standard drugs for Mycobacterium tuberculosis in animal models ($372,598, August 2021, completed June 2022); development and delivery of a quality assurance/quality control plan and task order initiation meeting support ($2,967.41, April 2021, completed August 2021); and funding of the guaranteed minimum amount ($0 value, October 2020, completed May 2021). All orders are priced cost-plus fixed fee or cost-no-fee and performed at the Galveston location.
Description
The contractor shall provide preclinical development support for candidate products and drug development activities. The scope of work encompasses activities that range from initial product discovery to those required to support clinical trials and/o
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93021D00011?
75N93021D00011 was awarded to University Of Texas Medical Branch At Galveston by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on October 15, 2020.
How much is contract 75N93021D00011 worth?
Orders under 75N93021D00011 have obligated $1,139,096. 75N93021D00011's own ceiling is $107,274,471.
How many orders have been placed under contract 75N93021D00011?
4 orders have been placed under 75N93021D00011, the latest on August 1, 2023.
Who can order from contract 75N93021D00011?
75N93021D00011 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N93021D00011 part of a contract vehicle?
Yes. 75N93021D00011 is part of Preclinical Services for HIV Therapeutics.
Was contract 75N93021D00011 competed?
The extent of competition for 75N93021D00011 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV